Maxim Affirms Inovio Pharma (INO) at 'Buy' Following Q4 Results, Asset Acquisition
Tweet Send to a Friend
Maxim affirmed Inovio Pharma (Nasdaq: INO) with a Buy rating and $14 price target following Q4 results and acquisition of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
